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For >4 decades, inferior vena cava (IVC) ﬁlters have been
used in some fashion for the treatment or prevention of acute
pulmonary embolism (PE) (1). The rationale is straightfor-
ward: trapping venous thrombi in transit without interrupting
venous ﬂow would prevent them from obstructing the pul-
monary arteries, impeding gas exchange and increasing the
demand on the right ventricle. IVC ﬁlters markedly reduce
embolization of deep venous thrombi into the lungs acutely,
even in patients who are receiving full-dose anticoagulation
(2). The option is particularly intuitive if anticoagulants
cannot be used in patients with venous thromboembolism
(VTE), for what else is left to offer them? However, intui-
tively “good ideas” do not always hold up to clinical testing.
In particular, clinical experience with IVC ﬁlters has not al-
ways supported their efﬁcacy (3).See page 1675In this issue of the Journal, Muriel et al. (4) report the
results of an intriguing study aimed at determining the effect
of IVC ﬁlter insertion on the mortality and morbidity of
patients suffering fromVTE in whom anticoagulation cannot
be used. The authors used data from the RIETE (Registro
Informatizado de la Enfermedad Tromboembólica) registry
of VTE patients and studied those in whom IVC ﬁlters
were placed because of severe risk of bleeding. Their outcomes
were compared with a subset of patients from the same
database who did not receive ﬁlters but were otherwise
matched according to clinical factors that are associated
with receiving IVC ﬁlters (e.g., bleeding, cancer, age). As
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disclose.anticoagulation therapy and experienced less recurrent
VTE during follow-up than those with ﬁlters. Despite this
ﬁnding, over the 30-day follow-up period, the IVC ﬁlter
group had lower rates of PE-related deaths and a trend toward
lower overall mortality. The authors concluded that, among
VTE patients with contraindications to anticoagulation, IVC
ﬁlter therapy may prevent PE-related deaths compared with
withholding IVC ﬁlters.
Muriel et al. (4) are to be congratulated for providing
good evidence to support the clinical intuition of placing
IVC ﬁlters in patients with VTE who have high bleeding
risks. It is unlikely that a conﬁrmatory randomized trial of
IVC ﬁlter placement will be performed on VTE patients
who cannot receive anticoagulants, in the absence of an
ethically sound alternative therapy. However, the study also
demonstrated that IVC ﬁlter–treated patients from this
registry experienced fewer PE-related deaths than clinically
similar patients who underwent anticoagulation therapy,
which suggests that ﬁlters offer clinical beneﬁts that are
discrete from those conferred by anticoagulation. Supportive
of the latter idea is the recent report by Stein et al. (5) that
IVC ﬁlter placement was associated with lower in-hospital
mortality in pharmacologically treated patients with severe
or unstable pulmonary emboli.
The observational data reported by Muriel et al. (4) and
others have posed the question of whether IVC ﬁlters should
complement the treatment of VTE patients who are at the
highest immediate risk of death from PE, regardless of
whether anticoagulation is administered. The stage seems
set for clinical trials to settle this important controversy.
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